

# Alexandre A S Soares

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9439529/publications.pdf>

Version: 2024-02-01

21  
papers

305  
citations

932766

10  
h-index

887659

17  
g-index

24  
all docs

24  
docs citations

24  
times ranked

588  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thromboelastometry demonstrates endogenous coagulation activation in nonsevere and severe COVID-19 patients and has applicability as a decision algorithm for intervention. PLoS ONE, 2022, 17, e0262600.	1.1	14
2	Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study. JMIR Research Protocols, 2021, 10, e24211.	0.5	3
3	Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology, 2021, 20, 74.	2.7	44
4	Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection (PROUDEST Trial): Protocol for a Multicenter, Prospective Cohort Study. JMIR Research Protocols, 2021, 10, e26477.	0.5	8
5	Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus. Nutrition and Diabetes, 2021, 11, 17.	1.5	8
6	Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction. International Journal of General Medicine, 2021, Volume 14, 3669-3676.	0.8	0
7	Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial. Diabetes and Metabolism, 2021, 47, 101280.	1.4	6
8	Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: an active-controlled randomised trial. Diabetes and Metabolism, 2021, 48, 101304.	1.4	1
9	Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial. Diabetology and Metabolic Syndrome, 2019, 11, 62.	1.2	9
10	Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1550-1564.	1.1	21
11	Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven. Revista Da Associa�o Mdica Brasileira, 2019, 65, 3-8.	0.3	2
12	Adverse interaction between HDL and the mass of myocardial infarction. Atherosclerosis, 2019, 281, 9-16.	0.4	8
13	Inflammatory Response During Myocardial Infarction. Advances in Clinical Chemistry, 2018, 84, 39-79.	1.8	26
14	HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction. Clinica Chimica Acta, 2018, 478, 51-56.	0.5	21
15	Pregnancy in Woman with Kawasaki Disease and Multiple Coronary Artery Aneurysms. Arquivos Brasileiros De Cardiologia, 2017, 110, 97-100.	0.3	4
16	Enhanced parathyroid hormone levels are associated with left ventricle hypertrophy in very elderly men and women. Journal of the American Society of Hypertension, 2015, 9, 697-704.	2.3	16
17	Low zinc levels is associated with increased inflammatory activity but not with atherosclerosis, arteriosclerosis or endothelial dysfunction among the very elderly. BBA Clinical, 2014, 2, 1-6.	4.1	28
18	C-reactive protein is independently associated with coronary atherosclerosis burden among octogenarians. Aging Clinical and Experimental Research, 2014, 26, 19-23.	1.4	12

#	ARTICLE	IF	CITATIONS
19	452 TIMING AND DOSE OF STATIN THERAPY DEFINE ITS IMPACT ON INFLAMMATORY AND ENDOTHELIAL RESPONSES DURING MYOCARDIAL INFARCTION. <i>Atherosclerosis Supplements</i> , 2011, 12, 96.	1.2	0
20	Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. <i>Atherosclerosis</i> , 2011, 216, 212-216.	0.4	38
21	Timing and Dose of Statin Therapy Define Its Impact on Inflammatory and Endothelial Responses During Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1240-1246.	1.1	36